Factors associated with maintenance of long-term plasma human immunodeficiency virus RNA suppression

Clinical Infectious Diseases

Volumn 37, Issue 5, 2003, Pages 702-707

  Holmberg, Scott D ^a,d   Hamburger, Merle E ^a   Moorman, Anne C ^a   Wood, Kathy C ^b   Palella Jr , Frank J ^c  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CERNER CORPORATION   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; EFAVIRENZ; INDINAVIR; LAMIVUDINE; VIRUS RNA;

ADULT; AGED; ARTICLE; CELL COUNT; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTPATIENT; PLASMA; PRIORITY JOURNAL; RISK; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DIDEOXYNUCLEOSIDES; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; MALE; OUTPATIENTS; OXAZINES; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; VIRAL LOAD;

EID: 0042331292     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/376992     Document Type: Article

References (16)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining mortality and morbidity in HIV-infected ambulatory patients. N Engl J Med 1998; 338:853-60.
2. Palella FJ Jr, Chmiel JM, Moorman AC, et al. Durability and predictors of success of highly active antiretroviral therapy (HAART) for ambulatory HIV-infected patients. AIDS 2002; 16:1-10.
3. Lampe FC, Johnson MA, Loveday C, et al. Recent trends in treatment use and virological suppression in a London HW clinic population [abstract 477-M]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). Alexandria, VA: Foundation for Retrovirology and Human Health, 2002:232.
4. + T-cell count gains in patients with 4 years of suppressed viral load on HAART [abstract 480-M]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). Alexandria, VA: Foundation for Retrovirology and Human Health, 2002:234.
5. Moorman AC, Holmberg SD, Marlowe SI, et al. Changing conditions and therapies of ambulatory HIV-infected patients: the HIV Outpatient Study (HOPS). Ann Epidemiol 1999; 9:349-57.
6. Sklar PA, Ward DJ, Baker RK, et al. Prevalence and clinical correlates of measurable HIV viremia ("blips") in patients with previous suppression below the limits of quantification. AIDS 16:2035-41.
7. Matthews GV, Sabin CA, Mandalia S, et al. Virologic suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study. AIDS 2002; 16:53-61.
8. Bartlett JA, Johnson J, Herrera G, Sosa N, Rodriguez AE. Abacavir/lamivudine (ABC/3TC) in combination with efavirenz (NNRTI), amprenavir/ritonavir (PI) or stavudine (NRTI): ESS40001 (CLASS) preliminary 48 week results [abstract TuOrB1189]. In: Program and abstracts of the 14th International Conference on AIDS (Barcelona, Spain). Vol 1. Barcelona, Spain: Barcelona AIDS 2002 Foundation, 2002:373.
9. Martinez C, Podzamczer D, Ribera C, et al. Switching protease inhibitors to nevirapine (NEV), efavirenz (EFA) or abacavir (ABA): a randomized, multicenter, open-label, simplification trial [abstract WeOrB1262]. In: Program and abstracts of the 14th International Conference on AIDS (Barcelona, Spain). Vol 2. Barcelona, Spain: Barcelona AIDS 2002 Foundation, 2002:28.
10. Kubota MK, Arroyo J, Canas A, et al. Successful intensification of antiretroviral therapy (ART) with abacavir (ABC) in clinical practice [abstract TuPeB4462]. In: Program and and abstracts of the 14th International Conference on AIDS (Barcelona, Spain). Vol 1. Barcelona, Spain: Barcelona AIDS 2002 Foundation, 2002:382.
11. Benson C, Quinn JB, Wakeford C, Moxham C, Rousseau F. Overview of the comparative effectiveness of triple combination therapy regimens of emtricitabine (FTC) and lamivudine (3TC) in antiretroviral-naive HIV-1 infected adults [abstract TuPeB4430]. In: Program and abstracts of the 14th International Conference on AIDS (Barcelona, Spain). Vol 1. Barcelona, Spain: Barcelona AIDS 2002 Foundation, 2002:375.
12. + subjects: comparison of sequential 3-drug regimens (ACTG 384) [abstract LBOR20A]. In: Program and abstracts of the 14th International Conference on AIDS (Barcelona, Spain). Supplement. Barcelona, Spain: Barcelona AIDS 2002 Foundation, 2002:26-7.
13. + T-cell gains in patients who continue combination therapy despite detectable viremia. AIDS 2002; 16:201-7.
14. Egger M, Ledergerber B, Grob P, et al. Viral replication and long-term clinical progression in patients treated with potent antiretroviral therapy [abstract 471-M]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). Alexandria, VA: Foundation for Retrovirology and Human Health, 2002:230.
15. Phillips AN, Grabar S, Tassle JM, Castagliola D, Lundgren JD, Egger M. Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials. AIDS 1999; 13:2075-82.
16. Havlir DV, Bassett R, Levitan D, et al. Prevalence and predictive value of intermittent viremia with combination HIV therapy. JAMA 2001; 286:171-9.